Summer Xia, Hasten Biopharma CEO
April 21, 2023 06:57 AM EDT
Financing
China

Chi­nese biotech start­up adds $315M to the bank af­ter bring­ing 5 Take­da drugs to its fold

Amber Tong

Senior Editor

More than two years af­ter ar­riv­ing on the Chi­na bio­phar­ma scene with a $322 mil­lion deal for five of Take­da’s drugs, Has­ten Bio­phar­ma has land­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

FDA re­jects Dai­ichi Sanky­o's HER3 ADC, a blow to quick ap­proval plans for Mer­ck part­ner­ship

Ab­b­Vie buys Third Rock­'s Cel­sius for $250M to ex­pand IBD pipeline

Maze spins its ALS an­ti­sense pro­gram in­to a se­cre­tive new com­pa­ny

Q&A: Ver­tex’s pain re­search chief on mov­ing be­yond opi­oids, AI and how phar­ma ac­qui­si­tions thrive or fail

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

A service from the Financial Times